Marinus Pharmaceuticals reported $21.05M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 116.57M 1.11M
Amgen AMGN:US USD 15.69B 1.36B
Aptinyx Inc APTX:US USD 2.69M 2.99M
Biogen BIIB:US USD 3.93B 1.09B
Eisai 4523:JP JPY 266.54B 35.36B
Enanta Pharmaceuticals ENTA:US USD 29.83M 6.79M
Esperion Therapeutics ESPR:US USD 82.34M 70K
Gilead Sciences GILD:US USD 10.42B 1.2B
Intercept Pharmaceuticals ICPT:US USD 221.58M 70.16M
Intra Cellular Therapies ITCI:US USD 77.41M 6.78M
Marinus Pharmaceuticals MRNS:US USD 21.05M 2.06M
Minerva Neurosciences NERV:US USD 2.2M 1.21M
Neurocrine Biosciences NBIX:US USD 485.1M 199.4M
Ptc Therapeutics PTCT:US USD 420.08M 147.29M
Regeneron Pharmaceuticals REGN:US USD 2.88B 154.7M
Sarepta Therapeutics SRPT:US USD 602.92M 57.35M
Supernus Pharmaceuticals SUPN:US USD 725.99M 9.55M
Vertex Pharmaceuticals VRTX:US USD 2.61B 53.1M
YTE INCY:US USD 1.01B 79.92M